[go: up one dir, main page]

EP3768707A4 - Compositions et procédés pour lymphocytes b modifiés exprimant des agents biologiques réattribués - Google Patents

Compositions et procédés pour lymphocytes b modifiés exprimant des agents biologiques réattribués Download PDF

Info

Publication number
EP3768707A4
EP3768707A4 EP19771532.9A EP19771532A EP3768707A4 EP 3768707 A4 EP3768707 A4 EP 3768707A4 EP 19771532 A EP19771532 A EP 19771532A EP 3768707 A4 EP3768707 A4 EP 3768707A4
Authority
EP
European Patent Office
Prior art keywords
compositions
modified
methods
cells expressing
biological agents
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP19771532.9A
Other languages
German (de)
English (en)
Other versions
EP3768707A1 (fr
Inventor
Roderick A. Hyde
Wayne R. Kindsvogel
Gary L. Mcknight
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Invention Science Fund II LLC
Original Assignee
Invention Science Fund II LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US15/924,898 external-priority patent/US10745468B2/en
Application filed by Invention Science Fund II LLC filed Critical Invention Science Fund II LLC
Publication of EP3768707A1 publication Critical patent/EP3768707A1/fr
Publication of EP3768707A4 publication Critical patent/EP3768707A4/fr
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/13—B-cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
    • A61K40/24—Antigen-presenting cells [APC]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4274—Prostate associated antigens e.g. Prostate stem cell antigen [PSCA]; Prostate carcinoma tumor antigen [PCTA]; Prostatic acid phosphatase [PAP]; Prostate-specific G-protein-coupled receptor [PSGR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/46—Viral antigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1018—Orthomyxoviridae, e.g. influenza virus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1081—Togaviridae, e.g. flavivirus, rubella virus, hog cholera virus
    • C07K16/109—Hepatitis C virus; Hepatitis G virus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1267—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria
    • C07K16/1271—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria from Micrococcaceae (F), e.g. Staphylococcus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3069—Reproductive system, e.g. ovaria, uterus, testes, prostate
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/44—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0635—B lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/58—Prostate
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/16043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Virology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Communicable Diseases (AREA)
  • General Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Pulmonology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
EP19771532.9A 2018-03-19 2019-03-15 Compositions et procédés pour lymphocytes b modifiés exprimant des agents biologiques réattribués Pending EP3768707A4 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US15/924,898 US10745468B2 (en) 2011-12-22 2018-03-19 Compositions and methods for modified B cells expressing reassigned biological agents
PCT/US2019/022572 WO2019182910A1 (fr) 2018-03-19 2019-03-15 Compositions et procédés pour lymphocytes b modifiés exprimant des agents biologiques réattribués

Publications (2)

Publication Number Publication Date
EP3768707A1 EP3768707A1 (fr) 2021-01-27
EP3768707A4 true EP3768707A4 (fr) 2022-01-26

Family

ID=67986343

Family Applications (1)

Application Number Title Priority Date Filing Date
EP19771532.9A Pending EP3768707A4 (fr) 2018-03-19 2019-03-15 Compositions et procédés pour lymphocytes b modifiés exprimant des agents biologiques réattribués

Country Status (3)

Country Link
EP (1) EP3768707A4 (fr)
CN (1) CN112105641A (fr)
WO (1) WO2019182910A1 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116829160A (zh) * 2020-09-02 2023-09-29 步行鱼治疗学股份有限公司 经修饰的b细胞及其使用方法

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130164784A1 (en) * 2011-12-22 2013-06-27 Elwha LLC, a limited liability company of the State of Delaware Compositions and methods including B lymphocyte cell line expressing membrane immunoglobulin different from secreted immunoglobulin
US20130164277A1 (en) * 2011-12-22 2013-06-27 Elwha LLC, a limited liability company of the State of Delaware Compositions and methods including B lymphocyte cell line expressing membrane immunoglobulin different from secreted immunoglobulin
US20160355783A1 (en) * 2011-12-22 2016-12-08 Elwha Llc Compositions and methods including b lymphocyte cell line expressing membrane immunoglobulin different from secreted immunoglobulin and cytolytic function
WO2017214376A1 (fr) * 2016-06-10 2017-12-14 Elwha Llc Compositions et procédés comprenant une lignée cellulaire de lymphocytes b exprimant une immunoglobuline membranaire différente d'une immunoglobuline sécrétée et fonction cytolytique

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003250074B2 (en) * 2002-07-18 2010-09-09 Merus N.V. Recombinant production of mixtures of antibodies
EP3045475B1 (fr) * 2008-04-02 2017-10-04 MacroGenics, Inc. Anticorps specifiques du complexe bcr et procedes pour les utiliser
WO2010003103A2 (fr) * 2008-07-02 2010-01-07 Whitehead Institute For Biomedical Research Mammifères non humains ayant des cellules t ou b à spécificité prédéterminée
KR101711222B1 (ko) * 2008-12-18 2017-02-28 에라스무스 유니버시티 메디컬 센터 로테르담 인간화 항체들을 발현하는 비-인간 유전자이식 동물들 및 그의 이용
EP2316920A1 (fr) * 2009-10-30 2011-05-04 BioNTech AG Expansion clonique de lymphocytes B
US10745468B2 (en) * 2011-12-22 2020-08-18 Kota Biotherapeutics, Llc Compositions and methods for modified B cells expressing reassigned biological agents
AU2016243052C1 (en) * 2015-04-03 2022-11-24 Dana-Farber Cancer Institute, Inc. Composition and methods of genome editing of B-cells
CN110022907A (zh) * 2016-10-10 2019-07-16 国家生物技术研究所公司 非细胞毒性的修饰细胞及其用途
EP3548622A1 (fr) * 2016-12-02 2019-10-09 Juno Therapeutics, Inc. Cellules b modifiées et compositions et méthodes associées
CN115552017A (zh) * 2020-03-31 2022-12-30 步行鱼治疗学公司 经修饰的b细胞及其使用方法
WO2023023596A1 (fr) * 2021-08-18 2023-02-23 The Trustees Of The University Of Pennsylvania Compositions et méthodes pour des récepteurs antigéniques chimériques spécifiques des récepteurs de lymphocytes b

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130164784A1 (en) * 2011-12-22 2013-06-27 Elwha LLC, a limited liability company of the State of Delaware Compositions and methods including B lymphocyte cell line expressing membrane immunoglobulin different from secreted immunoglobulin
US20130164277A1 (en) * 2011-12-22 2013-06-27 Elwha LLC, a limited liability company of the State of Delaware Compositions and methods including B lymphocyte cell line expressing membrane immunoglobulin different from secreted immunoglobulin
US20160355783A1 (en) * 2011-12-22 2016-12-08 Elwha Llc Compositions and methods including b lymphocyte cell line expressing membrane immunoglobulin different from secreted immunoglobulin and cytolytic function
WO2017214376A1 (fr) * 2016-06-10 2017-12-14 Elwha Llc Compositions et procédés comprenant une lignée cellulaire de lymphocytes b exprimant une immunoglobuline membranaire différente d'une immunoglobuline sécrétée et fonction cytolytique

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of WO2019182910A1 *

Also Published As

Publication number Publication date
CN112105641A (zh) 2020-12-18
EP3768707A1 (fr) 2021-01-27
WO2019182910A1 (fr) 2019-09-26

Similar Documents

Publication Publication Date Title
EP3664845A4 (fr) Compositions et procédés pour désactiver des cellules méyloïdes exprimant trem1
EP3573447A4 (fr) Compositions pour l'agriculture et procédés associés
EP3484994A4 (fr) Système crispr-cas pour une cellule hôte alguaire
DK3327141T3 (da) Fremgangsmåde til identificering af den cellulære sammensætning i en biologisk prøve
EP4001888C0 (fr) Réactif de coloration de tissu biologique, nécessaire de coloration de tissu biologique et méthode de coloration de tissu biologique
EP3573642A4 (fr) Compositions et procédés associés pour l'agriculture
EP3826468A4 (fr) Compositions pour l'agriculture et procédés associés
EP3641840A4 (fr) Échafaudages pour culture cellulaire et régénération de tissus
EP3935121A4 (fr) Matériau structurel vivant
EP3948223C0 (fr) Trieur de cellules intégré à bioconfinement
LT3375889T (lt) Vienos ląstelės analizė
EP3698397A4 (fr) Zones de référence adaptatives pour une inspection puce par puce
EP4053514A4 (fr) Biocapteur de plante
EP4013780A4 (fr) Lymphocytes t à car spécifiques pour des protéines modifiées dans des espaces extracellulaires
EP3744308C0 (fr) Récipient de collecte de sperme
EP3658590C0 (fr) Photoamorceurs pour compositions photodurcissables
EP3787314A4 (fr) Matériau de support pour sonde ultrasonore, son procédé de fabrication, et sonde ultrasonore
EP3075340C0 (fr) Ciseaux chirurgicaux pour tissus biologiques
EP3711114C0 (fr) Réseau d'antennes et son procédé de fabrication
EP3815549A4 (fr) Gyoza congelé et son procédé de production
EP3601541A4 (fr) Modèle de fus mutant pour la sla
EP3356515A4 (fr) Test d'activité biologique cellulaire
EP3630053C0 (fr) Composition pour fibres de kératine
EP4051918C0 (fr) Banc d'essai
EP4013854A4 (fr) Procédés de culture cellulaire

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20201005

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: THE INVENTION SCIENCE FUND II, LLC

A4 Supplementary search report drawn up and despatched

Effective date: 20220105

RIC1 Information provided on ipc code assigned before grant

Ipc: C12N 5/0781 20100101ALI20211222BHEP

Ipc: A61K 39/00 20060101ALI20211222BHEP

Ipc: C07K 16/00 20060101ALI20211222BHEP

Ipc: C07K 16/18 20060101AFI20211222BHEP